Casirivimab

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD Neutralizing Antibody (Casirivimab) is a research grade recombinant Human Monoclonal Antibody biosimilar against SARS-CoV-2/COVID-19 Spike Protein RBD.

The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.

Target	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD
Clonality	Monoclonal
Clone	REGN10933
Reactivity	Virus
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	ELISA: 1/5000 - 1/10000, WB: 1/1000 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	Recombinant SARS-CoV-2 RBD protein
Isotype	IgG
Form	Liquid
Purification	Purified by affinity chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	PBS, pH 7.5.
Specificity	Recognizes SARS-CoV-2 RBD Protein
Availability	Shipped within 5-12 working days.
Note	This product is for research use only.

Research Articles on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue